PALVELLA THERAPEUTICS, INC. - PVLA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 2.5% | 352,699 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 2.5% | 352,699 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 1.9% | 265,660 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 1.9% | 265,660 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.3% | 44,510 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.3% | 44,510 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 4.3% | 618,359 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 4.7% | 672,789 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF INC/IL | 4.7% | 672,789 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 4.7% | 672,789 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | First Light Asset Management, LLC | 5.34% | 769,117 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Mathew P. Arens | 5.34% | 769,117 | View |
| Aug 03, 2026 | SCHEDULE 13G | Jennison Associates LLC | 6.7% | 960,619 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.